Details

Autor(en) / Beteiligte

• Qi, Shu‐Nan
• Yang, Yong
• Zhang, Yu‐Jing
• Huang, Hui‐Qiang
• Wang, Ying
• He, Xia
• Zhang, Li‐Ling
• Wu, Gang
• Qu, Bao‐Lin
• Qian, Li‐Ting
• Hou, Xiao‐Rong
• Zhang, Fu‐Quan
• Qiao, Xue‐Ying
• Wang, Hua
• Li, Gao‐Feng
• Zhu, Yuan
• Cao, Jian‐Zhong
• Wu, Jun‐Xin
• Wu, Tao
• Zhu, Su‐Yu
• Shi, Mei
• Xu, Li‐Ming
• Yuan, Zhi‐Yong
• Su, Hang
• Song, Yu‐Qin
• Zhu, Jun
• Hu, Chen
• Li, Ye‐Xiong

Titel

Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK/T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study

Ist Teil von

• American journal of hematology, 2020-09, Vol.95 (9), p.1047-1056

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• We aimed to determine the survival benefits of chemotherapy (CT) added to radiotherapy (RT) in different risk groups of patients with early‐stage extranodal nasal‐type NK/T‐cell lymphoma (ENKTCL), and to investigate the risk of postponing RT based on induction CT responses. A total of 1360 patients who received RT with or without new‐regimen CT from 20 institutions were retrospectively reviewed. The patients had received RT alone, RT followed by CT (RT + CT), or CT followed by RT (CT + RT). The patients were stratified into different risk groups using the nomogram‐revised risk index (NRI). A comparative study was performed using propensity score‐matched (PSM) analysis. Adding new‐regimen CT to RT (vs RT alone) significantly improved overall survival (OS, 73.2% vs 60.9%, P < .001) and progression‐free survival (PFS, 63.5% vs 54.2%, P < .001) for intermediate‐risk/high‐risk patients, but not for low‐risk patients. For intermediate‐risk/high‐risk patients, RT + CT and CT + RT resulted in non‐significantly different OS (77.7% vs 72.4%; P = .290) and PFS (67.1% vs 63.1%; P = .592). For patients with complete response (CR) after induction CT, initiation of RT within or beyond three cycles of CT resulted in similar OS (78.2% vs 81.7%, P = .915) and PFS (68.2% vs 69.9%, P = .519). For patients without CR, early RT resulted in better PFS (63.4% vs 47.6%, P = .019) than late RT. Risk‐based, response‐adapted therapy involving early RT combined with CT is a viable, effective strategy for intermediate‐risk/high‐risk early‐stage patients with ENKTCL in the modern treatment era.